VivoSeq
Other

Erector Spinae Plane Block

2

Pipeline Programs

20

Active Trials

2

Companies Involved

Erector Spinae Plane Block is an early-stage landscape with 2 programs across 2 companies. The most active players are Fresenius Kabi Oncology Ltd., Eli Lilly. 2 programs are in Phase 3.

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

27/100

Mech. Concentration

100/100

Completion Rate

92/100

Attrition Rate

5/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Approved
No programs

Trial Status

99

clinical trials

Completed57 · 58%
Unknown status17 · 17%
Recruiting8 · 8%
Not yet recruiting6 · 6%
Active, not recruiting4 · 4%
Withdrawn3 · 3%
Other4 · 4%

Trial Activity

99 trials

Dexmedetomidine in Sonographic Guided Erector Spinae Plane Block
Recruiting··Phase 2/3·NCT06899841·90 enrolled
Effect of Patient Position on Erector Spinae Plane Block in Thoracic Surgery
Not yet recruiting··N/A·NCT07387484·90 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)